Although there is currently no effective treatment for prion diseases, significant advances have been made in suppressing its progress, using antibodies that block the conversion of PrPC into PrPSc. In order to be effective in treating individuals that have prion diseases, antibodies must be capable of arresting disease in its late stages. This requires the development of antibodies with higher affinity for PrPSc and systems for effective translocation of antibodies across the blood–brain barrier in order to achieve high concentrations of inhibitor at the site of protein replication. An additional advantage is the ability of these antibodies to access the cytosol of affected cells. To this end, we have generated PrP-specific antibodies (known as PrioV) by immunization of camels with murine scrapie material adsorbed to immunomagnetic beads. The PrioV antibodies display a range of specificities with some recognizing the PrP27–30 proteinase K-resistant fragment, others specific for PrPC and a number with dual binding specificity. Independent of their PrP conformation specificity, one of the PrioV antibodies (PrioV3) was shown to bind PrPC in the cytosol of neuroblastoma cells. In marked contrast, conventional anti-PrP antibodies produced in mouse against similar target antigen were unable to cross the neuronal plasma membrane and instead formed a ring around the cells. The PrioV anti-PrP antibodies could prove to be a valuable tool for the neutralization/clearance of PrPSc in intracellular compartments of affected neurons and could potentially have wider applicability for the treatment of so-called protein-misfolding diseases.
BarryR. A.,
VincentM. T.,
KentS. B.,
HoodL. E.,
PrusinerS. B.1988; Characterization of prion proteins with monospecific antisera to synthetic peptides. J Immunol 140:1188–1193
BessenR. A.,
MarshR. F.1992a; Biochemical and physical properties of the prion protein from two strains of the transmissible mink encephalopathy agent. J Virol 66:2096–2101
BessenR. A.,
MarshR. F.1992b; Identification of two biologically distinct strains of transmissible mink encephalopathy in hamsters. J Gen Virol 73:329–334
Curin SerbecV.,
BresjanacM.,
PopovicM.,
Pretnar HartmanK.,
GalvaniV.,
RuprehtR.,
CernilecM.,
VranacT.,
HafnerI.,
JeralaR.2004; Monoclonal antibody against a peptide of human prion protein discriminates between Creutzfeldt–Jacob's disease-affected and normal brain tissue. J Biol Chem 279:3694–3698
DecanniereK.,
DesmyterA.,
LauwereysM.,
GhahroudiM. A.,
MuyldermansS.,
WynsL.1999; A single-domain antibody fragment in complex with RNase A: non-canonical loop structures and nanomolar affinity using two CDR loops. Structure 7:361–370
EnariM.,
FlechsigE.,
WeissmannC.2001; Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc Natl Acad Sci U S A 98:9295–9299
GenoudN.,
OttD.,
BraunN.,
PrinzM.,
SchwarzP.,
SuterU.,
TronoD.,
AguzziA.2008; Antiprion prophylaxis by gene transfer of a soluble prion antagonist. Am J Pathol 172:1287–1296
HillA. F.,
JoinerS.,
BeckJ. A.,
CampbellT. A.,
DickinsonA.,
PoulterM.,
WadsworthJ. D.,
CollingeJ.2006; Distinct glycoform ratios of protease resistant prion protein associated with PRNP point mutations. Brain 129:676–685
KascsakR. J.,
RubensteinR.,
MerzP. A.,
Tonna-DeMasiM.,
FerskoR.,
CarpR. I.,
WisniewskiH. M.,
DiringerH.1987; Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins. J Virol 61:3688–3693
KorthC.,
StreitP.,
OeschB.1999; Monoclonal antibodies specific for the native, disease-associated isoform of the prion protein. Methods Enzymol 309:106–122
KrasemannS.,
GroschupM. H.,
HarmeyerS.,
HunsmannG.,
BodemerW.1996; Generation of monoclonal antibodies against human prion proteins in PrP0/0 mice. Mol Med 2:725–734
KrasemannS.,
JurgensT.,
BodemerW.1999; Generation of monoclonal antibodies against prion proteins with an unconventional nucleic acid-based immunization strategy. J Biotechnol 73:119–129
NishimuraT.,
SakudoA.,
XueG.,
IkutaK.,
YukawaM.,
SugiuraK.,
OnoderaT.2008; Establishment of a new glial cell line from hippocampus of prion protein gene-deficient mice. Biochem Biophys Res Commun 377:1047–1050
ParamithiotisE.,
PinardM.,
LawtonT.,
LaBoissiereS.,
LeathersV. L.,
ZouW. Q.,
EsteyL. A.,
LamontagneJ.,
LehtoM. T.other authors2003; A prion protein epitope selective for the pathologically misfolded conformation. Nat Med 9:893–899
PolymenidouM.,
MoosR.,
ScottM.,
SigurdsonC.,
ShiY. Z.,
YajimaB.,
Hafner-BratkovicI.,
JeralaR.,
HornemannS.other authors2008; The POM monoclonals: a comprehensive set of antibodies to non-overlapping prion protein epitopes. PLoS One 3:e3872
SongC. H.,
FuruokaH.,
KimC. L.,
OginoM.,
SuzukiA.,
HasebeR.,
HoriuchiM.2008; Effect of intraventricular infusion of anti-prion protein monoclonal antibodies on disease progression in prion-infected mice. J Gen Virol 89:1533–1544
TayebiM.,
EneverP.,
SattarZ.,
CollingeJ.,
HawkeS.2004; Disease-associated prion protein elicits immunoglobulin M responses in vivo . Mol Med 10:104–111
ThackrayA. M.,
HopkinsL.,
KleinM. A.,
BujdosoR.2007; Mouse-adapted ovine scrapie prion strains are characterized by different conformers of PrPSc
. J Virol 81:12119–12127
WhiteA. R.,
EneverP.,
TayebiM.,
MushensR.,
LinehanJ.,
BrandnerS.,
AnsteeD.,
CollingeJ.,
HawkeS.2003; Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 422:80–83
WilliamsonR. A.,
PeretzD.,
SmorodinskyN.,
BastidasR.,
SerbanH.,
MehlhornI.,
DeArmondS. J.,
PrusinerS. B.,
BurtonD. R.1996; Circumventing tolerance to generate autologous monoclonal antibodies to the prion protein. Proc Natl Acad Sci U S A 93:7279–7282
WilliamsonR. A.,
PeretzD.,
PinillaC.,
BallH.,
BastidasR. B.,
RozenshteynR.,
HoughtenR. A.,
PrusinerS. B.,
BurtonD. R.1998; Mapping the prion protein using recombinant antibodies. J Virol 72:9413–9418